DexCom earnings beat by $0.03, revenue topped estimates
NORTHBROOK, Ill. - IDEX Corporation (NYSE:IEX) reported mixed fourth quarter results, but its shares fell 1.4% after the company issued weaker-than-expected guidance for the first quarter of 2025.
The industrial manufacturing company posted adjusted earnings per share of $2.04 for Q4, edging past analyst expectations of $2.03. Revenue came in at $863 million, slightly below the consensus estimate of $868 million but up 9% year-over-year.
IDEX’s organic sales grew 3% in the quarter, driven by price increases and targeted growth initiatives across its segments. The company’s Health & Science Technologies segment saw the strongest growth, with sales up 19% due to the acquisition of Mott Corporation.
However, IDEX’s outlook for the first quarter fell short of expectations. The company forecasts Q1 2025 adjusted EPS of $1.60-$1.65, well below the $2.03 analysts were projecting. For the full year 2025, IDEX expects adjusted EPS of $8.10-$8.45, above the consensus of $7.88.
The company cited geopolitical and economic uncertainty heading into 2025, but expressed confidence in its target markets and ability to drive growth. IDEX aims to leverage its capabilities to focus resources on its best opportunities as it pursues double-digit earnings expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.